8-KLeadership Changes

STRYKER CORP 8-K Report, Executive Changes (Nov 9, 2020)

Filed November 9, 2020For Securities:SYK

Summary

Stryker Corporation (SYK) announced a strategic addition to its Board of Directors, electing Giovanni Caforio, M.D. to fill a newly created vacancy. This move, effective December 1, 2020, increases the Board's size from 10 to 11 members. Dr. Caforio brings extensive leadership experience from the pharmaceutical sector, most notably as CEO of Bristol Myers Squibb (BMS) since 2015, where he has spearheaded research and development in critical therapeutic areas and overseen significant acquisitions like Celgene. His appointment is particularly noteworthy given his deep background as a physician and his demonstrated ability to drive a patient-focused culture. Dr. Caforio's leadership at BMS and his current role as Chairman of PhRMA indicate a strong understanding of the healthcare and pharmaceutical landscape, which is expected to be a valuable asset to Stryker's strategic direction and governance. Compensation for his services will align with the company's standard practices for non-employee directors.

Key Highlights

  • 1Stryker Corporation elected Giovanni Caforio, M.D. to its Board of Directors.
  • 2The Board size was increased from 10 to 11 directors to accommodate the new appointment.
  • 3Dr. Caforio's appointment is effective December 1, 2020.
  • 4Dr. Caforio currently serves as CEO of Bristol Myers Squibb (BMS) and Chairman of its Board.
  • 5He has a strong background in pharmaceuticals, including leadership in R&D and the acquisition of Celgene.
  • 6Dr. Caforio's experience as a physician is expected to enhance the Board's perspective.
  • 7Compensation for Dr. Caforio will be consistent with Stryker's policy for non-employee directors.

Frequently Asked Questions

Giovanni Caforio, M.D. is a seasoned executive with extensive experience in the pharmaceutical industry. He has been the CEO of Bristol Myers Squibb (BMS) since May 2015 and assumed the role of Chairman of the BMS Board in May 2017. His tenure at BMS includes leading initiatives in oncology, hematology, immunology, and cardiovascular disease research, as well as overseeing the acquisition of Celgene. Prior to BMS, he held leadership positions at Abbott Laboratories and is currently the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Stryker's Board of Directors decided to increase its size from 10 to 11 members to accommodate the election of Dr. Giovanni Caforio. This suggests the company sought to leverage his specific expertise and leadership experience in the healthcare and pharmaceutical sectors to further enhance its strategic oversight and governance.

Dr. Caforio will receive compensation for his services as a director consistent with Stryker Corporation's established practices for its non-employee directors. Details regarding this compensation can be found in the company's proxy statement for its 2020 annual meeting of stockholders.

At the time of his appointment, Dr. Caforio had not yet been appointed to any committee of the Board of Directors. Future committee assignments would be subject to further Board decisions.